Pfizer Inc. (PFE) Key Metrics
PFE valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $168.60B
- Enterprise value
- $212.11B
- P/E (TTM)
- 38.9 10-yr median 16.7
- Forward P/E
- 9.7
- PEG ratio
- 12.89
- Price / sales
- 2.6 10-yr median 2.8
- Price / book
- 1.9 10-yr median 2.5
- EV / EBITDA
- 15.7 10-yr median 11.4
- Dividend yield
- 5.81% $1.72 a year
- Beta
- 0.28
PFE key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPFE valuation Price multiples at each fiscal year-end price.
PFE returns How much profit the business earns on the capital it uses.
PFE per-share figures Results divided by the shares outstanding at year-end.
PFE financial health Debt, liquidity and how easily interest is covered.
PFE efficiency & capital use Working capital cycle and where the cash goes.
PFE valuation history
PFE returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PFE debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PFE cash returned to shareholders
PFE price vs earnings per share
PFE key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $141.58B | $151.22B | $164.36B | $293.76B | $337.06B | $207.31B | $210.96B | $247.53B | $41.64B | $37.96B |
| Enterprise value | $195.40B | $197.74B | $226.71B | $306.86B | $344.42B | $234.93B | $253.27B | $270.44B | $65.12B | $62.20B |
| P/E ratio | 18.2 | 18.9 | 77.1 | 9.4 | 15.2 | 22.6 | 13.0 | 22.2 | 2.0 | 5.3 |
| Price / sales | 2.3 | 2.4 | 2.8 | 2.9 | 4.1 | 5.0 | 5.1 | 4.6 | 0.8 | 0.7 |
| Price / book | 1.6 | 1.7 | 1.8 | 3.1 | 4.4 | 3.3 | 3.3 | 3.9 | 0.6 | 0.6 |
| Price / free cash flow | 15.6 | 15.4 | 34.3 | 11.3 | 11.3 | 17.9 | 21.1 | 18.2 | 2.9 | 2.7 |
| Price / operating cash flow | 12.1 | 11.9 | 18.9 | 10.0 | 10.3 | 14.4 | 16.8 | 15.6 | 2.5 | 2.4 |
| EV / sales | 3.1 | 3.1 | 3.8 | 3.1 | 4.2 | 5.6 | 6.2 | 5.0 | 1.2 | 1.2 |
| EV / EBITDA | 11.6 | 10.9 | 23.7 | 7.5 | 11.2 | 17.7 | 13.5 | 13.8 | 3.3 | 4.1 |
| EV / free cash flow | 21.5 | 20.1 | 47.3 | 11.8 | 11.5 | 20.2 | 25.3 | 19.8 | 4.6 | 4.5 |
| Earnings yield | 5.5% | 5.3% | 1.3% | 10.7% | 6.6% | 4.4% | 7.7% | 4.5% | 51.2% | 19.0% |
| Free cash flow yield | 6.4% | 6.5% | 2.9% | 8.9% | 8.9% | 5.6% | 4.7% | 5.5% | 34.2% | 36.6% |
| Dividend yield | 6.9% | 6.3% | 5.6% | 3.1% | 2.6% | 4.1% | 3.8% | 3.2% | 18.4% | 19.3% |
| Shareholder yield (dividends + buybacks) | 6.9% | 6.3% | 5.6% | 3.7% | 2.6% | 4.1% | 8.0% | 8.2% | 30.4% | 32.4% |
| Share price at fiscal year-end | $24.90 | $26.53 | $28.79 | $51.24 | $59.05 | $36.81 | $37.17 | $41.41 | $34.36 | $30.82 |
| Per share | ||||||||||
| Revenue per share | $11.01 | $11.16 | $10.43 | $17.50 | $14.24 | $7.40 | $7.25 | $8.98 | $43.37 | $42.88 |
| Earnings per share | $1.37 | $1.41 | $0.37 | $5.47 | $3.88 | $1.63 | $2.87 | $1.87 | $17.58 | $5.86 |
| Operating cash flow per share | $2.06 | $2.24 | $1.52 | $5.11 | $5.71 | $2.56 | $2.22 | $2.65 | $13.59 | $12.91 |
| Free cash flow per share | $1.60 | $1.73 | $0.84 | $4.54 | $5.23 | $2.06 | $1.76 | $2.28 | $11.76 | $11.29 |
| Cash per share | $2.39 | $3.59 | $2.22 | $3.97 | $5.44 | $2.17 | $1.73 | $3.15 | $16.50 | $14.49 |
| Book value per share | $15.21 | $15.47 | $15.64 | $16.73 | $13.57 | $11.27 | $11.18 | $10.67 | $59.14 | $48.58 |
| Tangible book value per share | −$6.77 | −$6.27 | −$7.60 | $0.20 | $0.54 | −$2.59 | −$5.39 | −$4.16 | −$27.27 | −$38.36 |
| Dividends per share | $1.72 | $1.67 | $1.62 | $1.57 | $1.53 | $1.50 | $1.42 | $1.33 | $6.32 | $5.94 |
| Capex per share | $0.46 | $0.51 | $0.68 | $0.56 | $0.47 | $0.50 | $0.46 | $0.37 | $1.83 | $1.62 |
| Debt per share | $11.86 | $11.75 | $13.14 | $6.25 | $6.73 | $7.07 | $9.19 | $6.98 | $35.88 | $34.17 |
| Shares outstanding | 5.69B | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B | 5.67B | 5.98B | 1.21B | 1.23B |
| Change in shares outstanding | −0.2% | −0.2% | −0.4% | +0.4% | +1.3% | −0.8% | −5.1% | +393.3% | −1.6% | −1.6% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 8.9% | 9.0% | 2.3% | 36.2% | 31.4% | 14.4% | 25.6% | 16.5% | 32.4% | 11.6% |
| Return on invested capital (ROIC) | 11.2% | 11.5% | 4.1% | 35.0% | 21.8% | 8.7% | 7.4% | 15.8% | 16.1% | 15.0% |
| Return on assets (ROA) | 3.7% | 3.6% | 1.0% | 16.6% | 13.2% | 5.7% | 10.0% | 6.7% | 12.4% | 4.3% |
| Return on tangible assets | 9.3% | 9.0% | 2.3% | 30.6% | 20.7% | 12.0% | 22.2% | 15.8% | 31.7% | 11.2% |
| Free cash flow margin | 14.5% | 15.5% | 8.0% | 25.9% | 36.7% | 27.9% | 24.3% | 25.4% | 27.1% | 26.3% |
| Income quality (OCF / net income) | 1.51 | 1.59 | 4.08 | 0.93 | 1.47 | 1.57 | 0.77 | 1.42 | 0.77 | 2.20 |
| Financial health | ||||||||||
| Total debt | $67.42B | $66.99B | $75.04B | $35.83B | $38.44B | $39.84B | $52.15B | $41.74B | $43.48B | $42.09B |
| Cash & short-term investments | $13.60B | $20.48B | $12.69B | $22.73B | $31.07B | $12.22B | $9.83B | $18.83B | $19.99B | $17.85B |
| Net debt | $53.82B | $46.52B | $62.35B | $13.10B | $7.37B | $27.61B | $42.31B | $22.91B | $23.49B | $24.24B |
| Debt / equity | 0.78 | 0.76 | 0.84 | 0.37 | 0.50 | 0.63 | 0.82 | 0.65 | 0.61 | 0.70 |
| Debt / assets | 0.32 | 0.31 | 0.33 | 0.18 | 0.21 | 0.26 | 0.31 | 0.26 | 0.25 | 0.25 |
| Net debt / EBITDA | 3.21 | 2.57 | 6.52 | 0.32 | 0.24 | 2.08 | 2.25 | 1.17 | 1.18 | 1.58 |
| Current ratio | 1.16 | 1.17 | 0.91 | 1.22 | 1.40 | 1.35 | 0.88 | 1.57 | 1.35 | 1.25 |
| Quick ratio | 0.87 | 0.92 | 0.69 | 1.00 | 1.19 | 1.04 | 0.66 | 1.33 | 1.10 | 1.03 |
| Interest coverage | 5.8 | 5.3 | 2.4 | 30.3 | 16.1 | 6.3 | 4.8 | 11.6 | 11.3 | 12.0 |
| Working capital | $5.91B | $7.36B | −$4.46B | $9.12B | $17.02B | $9.15B | −$4.50B | $18.07B | $10.71B | $7.83B |
| Invested capital | $140.30B | $134.72B | $151.64B | $109.01B | $84.83B | $91.09B | $105.76B | $86.67B | $95.14B | $84.08B |
| Tangible asset value | −$38.22B | −$35.44B | −$43.40B | $1.17B | $3.11B | −$14.58B | −$30.58B | −$24.86B | −$33.04B | −$47.26B |
| Net current asset value | −$78.49B | −$74.54B | −$93.88B | −$50.03B | −$44.32B | −$55.69B | −$71.24B | −$45.74B | −$59.00B | −$72.83B |
| Graham number | $21.62 | $22.13 | $11.47 | $45.38 | $34.42 | $20.31 | $26.86 | $21.16 | $152.97 | $80.01 |
| Graham net-net per share | −$15.93 | −$15.42 | −$19.45 | −$11.02 | −$9.92 | −$11.74 | −$14.28 | −$10.80 | −$56.05 | −$66.64 |
| Capital allocation | ||||||||||
| Dividends paid | $9.77B | $9.51B | $9.25B | $8.98B | $8.73B | $8.44B | $8.04B | $7.98B | $7.66B | $7.32B |
| Share buybacks (net) | — | $0 | $0 | $2.00B | $0 | $0 | $8.87B | $12.20B | $5.00B | $5.00B |
| Dividend payout ratio | 125.8% | 118.6% | 433.5% | 28.6% | 39.4% | 92.1% | 49.4% | 71.5% | 35.9% | 101.4% |
| Dividends + buybacks / free cash flow | 107.7% | 96.7% | 192.9% | 42.2% | 29.2% | 72.7% | 169.2% | 148.0% | 88.8% | 88.6% |
| Capex / revenue | 4.2% | 4.6% | 6.6% | 3.2% | 3.3% | 6.7% | 6.3% | 4.1% | 4.2% | 3.8% |
| Capex / operating cash flow | 22.5% | 22.8% | 44.9% | 11.1% | 8.3% | 19.4% | 20.6% | 13.9% | 13.5% | 12.6% |
| Capex / depreciation | 0.40 | 0.41 | 0.62 | 0.64 | 0.52 | 0.58 | 0.43 | 0.34 | 0.35 | 0.35 |
| Stock-based compensation / revenue | 1.3% | 1.4% | 0.9% | 0.9% | 1.5% | 1.8% | 1.7% | 1.8% | 1.6% | 1.3% |
| R&D / revenue | 19.1% | 16.9% | 17.8% | 11.4% | 17.0% | 22.6% | 20.3% | 14.9% | 14.5% | 14.8% |
| SG&A / revenue | 21.8% | 23.2% | 24.8% | 10.8% | 15.6% | 27.9% | 29.3% | 26.9% | 28.1% | 28.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 89.3 | 74.4 | 78.8 | 55.1 | 60.5 | 101.9 | 104.0 | 77.1 | 78.3 | 76.4 |
| Days of inventory on hand | 211.4 | 176.3 | 119.8 | 86.1 | 90.7 | 253.2 | 228.3 | 172.0 | 166.1 | 163.5 |
| Days payables outstanding | 106.9 | 103.4 | 84.5 | 59.1 | 52.4 | 132.2 | 128.6 | 106.4 | 106.3 | 93.3 |
| Cash conversion cycle (days) | 193.8 | 147.3 | 114.1 | 82.0 | 98.8 | 222.9 | 203.7 | 142.7 | 138.1 | 146.6 |
| Receivables turnover | 4.09 | 4.90 | 4.63 | 6.63 | 6.03 | 3.58 | 3.51 | 4.73 | 4.66 | 4.78 |
| Payables turnover | 3.41 | 3.53 | 4.32 | 6.17 | 6.96 | 2.76 | 2.84 | 3.43 | 3.43 | 3.91 |
| Inventory turnover | 1.73 | 2.07 | 3.05 | 4.24 | 4.02 | 1.44 | 1.60 | 2.12 | 2.20 | 2.23 |
| Asset turnover | 0.30 | 0.29 | 0.28 | 0.53 | 0.48 | 0.26 | 0.25 | 0.32 | 0.31 | 0.31 |
| Average receivables | $15.31B | $12.98B | $12.85B | $15.14B | $13.47B | $11.63B | $11.73B | $11.34B | $11.27B | $11.05B |
| Average payables | $5.44B | $6.17B | $6.76B | $6.19B | $4.94B | $4.26B | $4.45B | $4.67B | $4.60B | $4.08B |
| Average inventory | $10.75B | $10.52B | $9.59B | $9.02B | $8.55B | $8.16B | $7.90B | $7.54B | $7.18B | $7.15B |
| Intangibles / total assets | 60.0% | 58.1% | 58.6% | 48.0% | 41.0% | 50.6% | 56.1% | 55.6% | 60.9% | 62.4% |
Computed from PFE's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PFE valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Pfizer traded at 18.2 times earnings, against a 10-year median of 16.7. Based on the latest twelve months, the trailing P/E is 38.9 and the forward P/E is 9.7. Pfizer earned a return on equity of 8.9% and a return on invested capital of 11.2% in fiscal 2025. It ended the year with $67.4 billion of debt and $13.6 billion in cash and short-term investments, net debt of $53.8 billion. It returned $9.8 billion to shareholders: $9.8 billion in dividends and $0 in share buybacks, 108% of free cash flow. The share count rose 361.6% from 1.23B to 5.69B over 9 years.
See the PFE income statement, the PFE chart for price history, or the PFE stock overview for the latest quote and news.
PFE key metrics FAQ
What is Pfizer's P/E ratio?
Pfizer's trailing P/E ratio is 38.9 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.7. At the end of fiscal 2025 it was 18.2, compared with a 10-year median of 16.7.
What is Pfizer's EV/EBITDA?
Pfizer's enterprise value was 11.6 times EBITDA at the end of fiscal 2025 (enterprise value $195.4 billion, EBITDA $16.8 billion); the current EV/EBITDA is 15.7.
What is Pfizer's return on equity?
Pfizer's return on equity (ROE) was 8.9% in fiscal 2025: net income of $7.8 billion on average shareholders' equity of $87.3 billion.
What is Pfizer's ROIC?
Pfizer's return on invested capital was 11.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Pfizer have?
Pfizer had total debt of $67.4 billion at the end of fiscal 2025, a debt-to-equity ratio of 0.78 and $53.8 billion of net debt (3.21 times EBITDA).
What is Pfizer's dividend yield?
Pfizer's forward dividend yield is 5.81%. Pfizer paid $9.8 billion in dividends in fiscal 2025 ($1.72 per share), a payout ratio of 125.8%.
What is Pfizer's free cash flow yield?
Pfizer generated $9.1 billion of free cash flow in fiscal 2025, a free cash flow yield of 6.4% on its market value at year-end ($141.6 billion).
What is Pfizer's current ratio?
Pfizer's current ratio was 1.16 at the end of fiscal 2025: current assets were 1.16 times current liabilities.